Skip Navigation


Annals of Oncology Advance Access originally published online on January 27, 2005
Annals of Oncology 2005 16(3):345-351; doi:10.1093/annonc/mdi094
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME/CE:
Take the course for this article:
 Annals of Oncology course: issues - J...
Right arrow All Versions of this Article:
16/3/345    most recent
mdi094v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Steele, J. P. C.
Right arrow Articles by Klabatsa, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steele, J. P. C.
Right arrow Articles by Klabatsa, A.
Related Collections
Right arrow 2005 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Review

Chemotherapy options and new advances in malignant pleural mesothelioma

J. P. C. Steele* and A. Klabatsa

Mesothelioma Research Group, St Bartholomew's Hospital and Medical College, London, UK

* Correspondence to: Dr J. P. C. Steele, Mesothelioma Research Group, Department of Medical Oncology, St Bartholomew's Hospital, West Smithfield, London EC1A 7BE, UK. Tel: +44-20-7601-7900; Fax: +44-20-7601-7577; Email: jeremy.steele{at}bartsandthelondon.nhs.uk

Malignant pleural mesothelioma continues to be a challenging clinical problem. While traditionally, chemotherapy has been thought to be of only modest benefit to patients with this disease, novel antineoplastic agents and combination regimens incorporating these agents are gradually changing this perception. Early attempts at treatment and palliation with single agents such as doxorubicin met with low response rates and little clinical benefit. However, the recently reported clinical benefits of pemetrexed and raltitrexed in combination with cisplatin are changing the perception about the ability of chemotherapy to affect the natural history of the disease. Other combinations, including cisplatin and gemcitabine, have also shown encouraging response rates and clinical activity. Single-agent therapy with vinorelbine may provide useful palliation with low toxicity. Targeted agents developed through increased understanding of the biology of the disease, used alone or as part of multimodal therapy, may provide major clinical gains in the next few years.

Key words: cancer, chemotherapy, mesothelioma, novel agents


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
D. Barbone, T.-M. Yang, J. R. Morgan, G. Gaudino, and V. C. Broaddus
Mammalian Target of Rapamycin Contributes to the Acquired Apoptotic Resistance of Human Mesothelioma Multicellular Spheroids
J. Biol. Chem., May 9, 2008; 283(19): 13021 - 13030.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
A Chapman, S Mulrennan, B Ladd, and M F Muers
Population based epidemiology and prognosis of mesothelioma in Leeds, UK
Thorax, May 1, 2008; 63(5): 435 - 439.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Bottomley, C. Coens, F. Efficace, R. Gaafar, C. Manegold, S. Burgers, M. Vincent, C. Legrand, and J. P. van Meerbeeck
Symptoms and Patient-Reported Well-Being: Do They Predict Survival in Malignant Pleural Mesothelioma? A Prognostic Factor Analysis of EORTC-NCIC 08983: Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma
J. Clin. Oncol., December 20, 2007; 25(36): 5770 - 5776.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. C. Talbot, J. Margery, G. Dabouis, G. Dark, H. Taylor, H. Boussemart, V. Cadic, M.-C. Pinel, A. Riviere, L. Ollivier, et al.
Phase II Study of Vinflunine in Malignant Pleural Mesothelioma
J. Clin. Oncol., October 20, 2007; 25(30): 4751 - 4756.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
G. L. Ceresoli, C. Gridelli, and A. Santoro
Multidisciplinary Treatment of Malignant Pleural Mesothelioma
Oncologist, July 1, 2007; 12(7): 850 - 863.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. L. Ceresoli, P. A. Zucali, A. G. Favaretto, F. Grossi, P. Bidoli, G. Del Conte, A. Ceribelli, A. Bearz, E. Morenghi, R. Cavina, et al.
Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma
J. Clin. Oncol., March 20, 2006; 24(9): 1443 - 1448.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. K. Nowak and M. J. Byrne
Cisplatin and gemcitabine in malignant mesothelioma
Ann. Onc., October 1, 2005; 16(10): 1711 - 1711.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Xia, S. R. Kumar, R. Masood, M. Koss, C. Templeman, D. Quinn, S. Zhu, R. Reddy, V. Krasnoperov, and P. S. Gill
Up-Regulation of EphB4 in Mesothelioma and Its Biological Significance
Clin. Cancer Res., June 15, 2005; 11(12): 4305 - 4315.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.